Product Description
Mechanisms of Action: HCV-NS3/4A Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Japan
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Hepatitis A|Hepatitis C, Chronic
Phase 2: Hepatitis A|Hepatitis C, Chronic|Hepatitis C|Communicable Diseases
Phase 1: Hepatitis C|Hepatitis C, Chronic|Hepatitis A|Liver Failure|Hepatic Insufficiency
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
MK-7009-048 | P1 |
Completed |
Hepatitis C, Chronic|Hepatitis A |
2013-08-27 |
|
MK-7009-043 | P3 |
Completed |
Hepatitis A|Hepatitis C, Chronic |
2013-07-31 |
|
MK-7009-028 | P2 |
Completed |
Hepatitis C, Chronic|Hepatitis A |
2013-05-29 |
|
2009-013053-15 | P2 |
Completed |
Hepatitis C |
2013-05-29 |